Bio-Rad Laboratories, Inc. Stock price

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 11:27:43 2024-03-28 am EDT 5-day change 1st Jan Change
346.1 USD -0.99% Intraday chart for Bio-Rad Laboratories, Inc. -1.91% +6.93%
Sales 2024 * 2.72B Sales 2025 * 2.87B Capitalization 9.88B
Net income 2024 * 444M Net income 2025 * 509M EV / Sales 2024 * 3.39 x
Net cash position 2024 * 661M Net cash position 2025 * 1.24B EV / Sales 2025 * 3.01 x
P/E ratio 2024 *
22.9 x
P/E ratio 2025 *
20 x
Employees 8,030
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.01%
More Fundamentals * Assessed data
Dynamic Chart
Biodesix Strikes New Research Deal With Memorial Sloan Kettering Cancer Center MT
Bio-Rad Laboratories Appoints Roop Lakkaraju as CFO MT
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as Chief Financial Officer, Effective April 15, 2024 CI
Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024 CI
Transcript : Bio-Rad Laboratories, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 02:30 PM
Bio-rad Laboratories Insider Sold Shares Worth $1,008,000, According to a Recent SEC Filing MT
UBS Adjusts Bio-Rad Laboratories Price Target to $420 From $395, Maintains Buy Rating MT
RBC Trims Price Target on Bio-Rad Laboratories to $480 From $484, Keeps Outperform Rating MT
Bio Rad Labs rises after posting upbeat fourth-quarter profit RE
Bio-Rad Laboratories Q4 Adjusted Earnings, Revenue Decline, Shares Rise After-Hours MT
Transcript : Bio-Rad Laboratories, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (BIO.B) BIO-RAD LABORATORIES Posts Q4 Revenue $681.2M, vs. Street Est of $686.6M MT
Earnings Flash (BIO.B) BIO-RAD LABORATORIES Reports Q4 EPS $3.10, vs. Street Est of $2.87 MT
Bio-Rad Laboratories, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer CI
More news
1 day+2.65%
1 week+3.95%
Current month+7.27%
1 month+6.01%
3 months+8.51%
6 months-0.83%
Current year+8.26%
More quotes
1 week
337.15
Extreme 337.1485
360.13
1 month
322.03
Extreme 322.03
360.13
Current year
302.65
Extreme 302.65
364.24
1 year
261.59
Extreme 261.59
494.05
3 years
261.59
Extreme 261.59
832.70
5 years
261.59
Extreme 261.59
832.70
10 years
102.71
Extreme 102.71
832.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 74 88-12-31
Director of Finance/CFO 77 83-01-31
Chief Operating Officer 64 19-04-21
Members of the board TitleAgeSince
Director/Board Member 64 17-04-24
Founder 97 51-12-31
Director/Board Member 77 17-04-24
More insiders
Date Price Change Volume
24-03-28 345.2 -1.26% 19 342
24-03-27 349.6 +2.65% 189,652
24-03-26 340.5 -0.17% 109,912
24-03-25 341.1 -2.67% 167,589
24-03-22 350.5 -0.43% 327,577

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
349.6 USD
Average target price
435.7 USD
Spread / Average Target
+24.65%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Bio-Rad Laboratories, Inc. - Nyse